Fenofibrate or silymarin for sepsis in adults
Treatments studied
Part of Infections clinical trials.
This study tests whether fenofibrate (a cholesterol medicine) or silymarin (an herbal extract) can help adults with sepsis recover. You may need to be in the hospital with an active infection to participate.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with sepsis (a severe infection that harms your body's organs)
- You are not in late-stage septic shock with many organs already failing
- You do not have serious stomach or intestinal disease, or liver or kidney failure that existed before this infection
- You are not pregnant or breastfeeding, and you do not have known allergies to the study drugs (fenofibrate or silymarin)
- You do not have cancer or are not taking immune-weakening medicines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether a drug called fisetin can slow the progression of sepsis once you are admitted to the hospital. It may help patients recover more quickly or avoid worsening, but eligibility depends on how severe the illness is and what other treatments you need.
This trial is testing several different treatments to find the best one for each person with sepsis. It looks at specific 'treatable traits' like inflammation, blood clotting problems, or immune system issues to match you with the right therapy. The goal is to improve recovery and survival.
This trial tests if curcumin (a natural compound found in turmeric) can help critically ill patients fighting sepsis, a life-threatening response to infection. It is for adults who are already receiving food through a feeding tube in the ICU.
This trial tests if a special blood-filtering method combined with plasma exchange can help people with severe liver failure and sepsis. It aims to reduce inflammation and improve survival.
This study tests a medicine called thymalfasin, which may help the immune system recover in adults with sepsis (a severe infection that causes organ damage). It aims to see if this treatment can improve immune function and possibly outcomes.
This study is for people with both cirrhosis and sepsis. It will follow their hospital course to better understand how these two conditions affect each other, which may help improve care for others in the future.
Hear when a new Sepsis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.